EE200100447A - N-[2-hüdroksü-3-(1-piperidinüül)propoksü]püridiin-1-oksiid-3-karboksimidoüülkloriid ning selle kasutamine insuliiniresistentsuse ravis - Google Patents

N-[2-hüdroksü-3-(1-piperidinüül)propoksü]püridiin-1-oksiid-3-karboksimidoüülkloriid ning selle kasutamine insuliiniresistentsuse ravis

Info

Publication number
EE200100447A
EE200100447A EEP200100447A EEP200100447A EE200100447A EE 200100447 A EE200100447 A EE 200100447A EE P200100447 A EEP200100447 A EE P200100447A EE P200100447 A EEP200100447 A EE P200100447A EE 200100447 A EE200100447 A EE 200100447A
Authority
EE
Estonia
Prior art keywords
insulin resistance
piperidinyl
propoxy
pyridine
hydroxy
Prior art date
Application number
EEP200100447A
Other languages
English (en)
Inventor
K�rthy M�ria
B�r� Katalin
Nagy K�roly
�r�gdi L�szl�
Cs�kai Zita
Szilbereky Jen�
Mogyor�si Tam�s
T�r�k Magdolna
Kom�romi Andr�s
M�rv�nyos Ede
Barab�s Mih�ly
Kardos Mih�lyn�
Nagy Zolt�n
Kor�nyi L�szl�
Nagy Melinda
Original Assignee
Biorex Kutat� �s Fejleszto Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutat� �s Fejleszto Rt. filed Critical Biorex Kutat� �s Fejleszto Rt.
Publication of EE200100447A publication Critical patent/EE200100447A/et
Publication of EE04961B1 publication Critical patent/EE04961B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200100447A 1999-02-26 2000-02-24 N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis EE04961B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
PCT/HU2000/000015 WO2000050403A1 (en) 1999-02-26 2000-02-24 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Publications (2)

Publication Number Publication Date
EE200100447A true EE200100447A (et) 2002-12-16
EE04961B1 EE04961B1 (et) 2008-02-15

Family

ID=90014224

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100447A EE04961B1 (et) 1999-02-26 2000-02-24 N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis

Country Status (27)

Country Link
US (1) US6649628B1 (et)
EP (1) EP1163224B1 (et)
JP (1) JP4689838B2 (et)
KR (1) KR100676124B1 (et)
AT (1) ATE237590T1 (et)
AU (1) AU779096B2 (et)
BG (1) BG65178B1 (et)
BR (1) BR0008969A (et)
CA (1) CA2360451C (et)
CZ (1) CZ297386B6 (et)
DE (1) DE60002187T2 (et)
DK (1) DK1163224T3 (et)
EE (1) EE04961B1 (et)
ES (1) ES2193055T3 (et)
HR (1) HRP20010584B1 (et)
HU (1) HUP9900475D0 (et)
IL (2) IL144866A0 (et)
NO (1) NO319793B1 (et)
PL (1) PL197692B1 (et)
PT (1) PT1163224E (et)
RS (1) RS50083B (et)
RU (1) RU2250901C2 (et)
SI (1) SI1163224T1 (et)
SK (1) SK287063B6 (et)
UA (1) UA72495C2 (et)
WO (1) WO2000050403A1 (et)
ZA (1) ZA200106488B (et)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
CA2471752A1 (en) 2002-01-11 2003-07-17 Biorex Kutato Es Fejlesztoe Rt. Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303584A3 (en) * 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
TW200831479A (en) * 2006-09-26 2008-08-01 Cytrx Corp Pharmaceutical compositions and methods for treating diseases
EP2484371B1 (en) 2008-06-26 2014-12-17 Orphazyme APS Use of Hsp70 as a regulator of enzymatic activity
KR20110084514A (ko) * 2008-11-18 2011-07-25 산텐 세이야꾸 가부시키가이샤 피리딘-3-카르발데히드 ｏ-(피페리딘-1-일-프로필)-옥심 유도체를 유효 성분으로서 함유하는 망맥락막 변성 질환의 치료제
RU2013125923A (ru) 2010-11-30 2015-01-10 Орфазиме Апс СПОСОБЫ УВЕЛИЧЕНИЯ ВНУТРИКЛЕТОЧНОЙ АКТИВНОСТИ Hsp70
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
PL2892540T3 (pl) * 2012-09-06 2018-12-31 Mcpharma Biotech Inc. Leczenie biegunki i biegunki po odsadzeniu przy pomocy opornej skrobi ziemniaczanej
ES2912524T3 (es) 2012-09-14 2022-05-26 Saint Gobain Cristal con un elemento de conexión eléctrica
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
US10709700B2 (en) * 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
EP3442530A1 (en) 2016-04-13 2019-02-20 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
SI3448382T1 (sl) 2016-04-29 2021-03-31 Orphazyme A/S, c/o COBIS A/S Arimoclomol za zdravljenje motenj, povezanih z glukocerebrozidazo
JP2020520947A (ja) 2017-05-24 2020-07-16 オーファザイム エー／エス 熱ショックタンパク質誘導因子および前頭側頭障害
US20210164997A1 (en) 2018-05-28 2021-06-03 Orphazyme A/S Hsp70 protein levels in pbmc samples as biomarker for disease
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
WO2021260120A1 (en) 2020-06-24 2021-12-30 Orphazyme A/S Arimoclomol for treating gaucher disease
CN116783164A (zh) * 2020-11-19 2023-09-19 泽维拉丹麦股份有限公司 制备柠檬酸阿瑞洛莫及其中间体的方法
WO2022106614A1 (en) * 2020-11-19 2022-05-27 Orphazyme A/S Processes for preparing arimoclomol citrate and intermediates thereof
JP2024502304A (ja) 2020-12-24 2024-01-18 ゼブラ デンマーク エー／エス Ｅｒ型ミスセンス変異を有する患者におけるニーマンピック病ｃ型の治療用アリモクロモル

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HU220971B1 (hu) * 1997-04-03 2002-07-29 BIOREX Kutató és Fejlesztő Rt. Eljárás 0-(3-amino-2-hidroxi-propil)-hidroximsav-halogenidek előállítására
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Also Published As

Publication number Publication date
SK11582001A3 (sk) 2001-12-03
AU3182400A (en) 2000-09-14
DE60002187T2 (de) 2003-12-11
IL144866A (en) 2007-07-04
ZA200106488B (en) 2002-08-07
WO2000050403A1 (en) 2000-08-31
NO20014103L (no) 2001-10-22
IL144866A0 (en) 2002-06-30
CA2360451C (en) 2011-01-04
PL350915A1 (en) 2003-02-10
SK287063B6 (sk) 2009-10-07
ES2193055T3 (es) 2003-11-01
NO20014103D0 (no) 2001-08-23
US6649628B1 (en) 2003-11-18
CZ20013053A3 (cs) 2002-01-16
AU779096B2 (en) 2005-01-06
PT1163224E (pt) 2003-07-31
RS50083B (sr) 2009-01-22
PL197692B1 (pl) 2008-04-30
BR0008969A (pt) 2001-11-27
DE60002187D1 (de) 2003-05-22
UA72495C2 (uk) 2005-03-15
KR100676124B1 (ko) 2007-01-31
BG105837A (en) 2002-03-29
ATE237590T1 (de) 2003-05-15
HUP9900475D0 (en) 1999-04-28
NO319793B1 (no) 2005-09-12
EP1163224A1 (en) 2001-12-19
DK1163224T3 (da) 2003-08-04
JP4689838B2 (ja) 2011-05-25
HRP20010584A2 (en) 2002-08-31
HRP20010584B1 (en) 2010-08-31
RU2250901C2 (ru) 2005-04-27
CA2360451A1 (en) 2000-08-31
SI1163224T1 (en) 2003-08-31
CZ297386B6 (cs) 2006-11-15
EE04961B1 (et) 2008-02-15
YU60301A (sh) 2004-05-12
JP2002537384A (ja) 2002-11-05
KR20010102410A (ko) 2001-11-15
EP1163224B1 (en) 2003-04-16
BG65178B1 (bg) 2007-05-31

Similar Documents

Publication Publication Date Title
EE04961B1 (et) N-[2-hdroks-3-(1-piperidinl)propoks]pridiin-1-oksiid-3-karboksimidolkloriid ning selle kasutamine insuliiniresistentsuse ravis
GB0223038D0 (en) Therapeutic compounds
EA200101166A1 (ru) Ингибиторы металлопротеаз
DE60019473D1 (de) (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
EE200400032A (et) Polüfenooliühendit sisaldav farmatseutiline toitekompositsioon ning selle kasutamine vähktõve ravimiseks
TW229205B (et)
CA2332521A1 (en) Pharmaceutical composition for treating or preventing sleep disorders
RU2001126126A (ru) N-[2-гидрокси-3-(1-пиперидинил)пропокси]пиридин-1-оксид-3-карбоксиимидоилхлорид и его применение при лечении невосприимчивости к инсулину
DE69931766D1 (de) Antitumorale mittel
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
IL131217A0 (en) Novel methods and compositions for delivery of taxanes
TR200101903T2 (tr) Yeni malonik asit türevleri, bunların preparasyon işlemleri.
FR2840903B1 (fr) Derive de glucose et de vitamine f, compositions le comprenant et utilisations pour ameliorer l'etat des poils et des cheveux
BR0210791A (pt) Composição tendo atividade bacteristática e bactericida contra esporos bacterianos e células vegetativas e processo para tratamento de alimentos utilizando a mesma
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
ATE320811T1 (de) Verwendung von beta-blatt mimetika als protease und kinase hemmer und alshemmer eines transkriptionsfaktors
BR0318185A (pt) composição para administração de ferro para o tratamento de sìndrome das pernas inquietas
ATE359804T1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1- inhibitoren zur behandlung von nierenkrankheiten
SE0102147D0 (sv) New methods
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
SE0401631L (sv) Ny sammansättning
TNSN99138A1 (fr) Une composition antioxydante, cytostatique et a support energetique qui ameliore l'utilisation metabolique du glucose
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
ATE395936T1 (de) Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten
WO1999051216A3 (en) 3-pyridyloxyalkylamine or aryloxyalkylamine derivatives as cholinergic agonists

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110224